Novartis AG ADR (NVS) News
Filter NVS News Items
NVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NVS News From Around the Web
Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. |
AI, vaccine distrust, & the future of healthcare: Novartis CEOCan science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price. In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episo... |
Light Horse emerges with $62m and Novartis partnership worth up to $1bnLight Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets. |
Are You a Momentum Investor? This 1 Stock Could Be the Perfect PickThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Why Novartis (NVS) is a Top Value Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & MorePFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study. |
Positive data could expand use of Novartis’ gene therapy for SMAZolgensma represents the first and only gene transfer therapy for the treatment of SMA. |
Novartis' Gene Therapy Meets Primary Endpoint in SMA StudyNVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal. |
Here's Why Novartis (NVS) is a Strong Growth StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Novartis’ Gene Therapy Shows Promise in Treating SMANovartis ( (NVS) ) has provided an update. Novartis announced the success of its Phase III STEER study for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in treating spinal muscular atrophy (SMA) Type 2 in children and young adults. The study demonstrated an increase in motor function, showcasing the therapy’s efficacy and safety compared to a sham control. Novartis plans to seek regulatory approval in 2025, which could enhance treatment options for SMA patients and strengthen |